Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00133991
Other study ID # J0409
Secondary ID P50CA096888P30CA
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2005
Est. completion date August 2013

Study information

Verified date September 2018
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with rituximab may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with newly diagnosed Burkitt's lymphoma or leukemia.


Description:

OBJECTIVES:

Primary

- Determine the overall response rate, 1-year event-free survival, and overall survival of adult patients with newly diagnosed Burkitt or atypical Burkitt lymphoma or leukemia treated with dose-intensified induction therapy comprising cyclophosphamide, vincristine, prednisone, and rituximab followed by consolidation therapy comprising rituximab and high-dose cyclophosphamide.

- Determine the grade 3 or higher non-hematologic toxic effects and overall tolerability of this regimen in these patients.

Secondary

- Determine the 3-year event-free survival and overall survival of patients treated with this regimen.

- Determine the general patterns of CNS and systemic relapse in patients treated with this regimen.

OUTLINE: This is a multicenter study.

- Dose-intensified CVP induction therapy: Patients receive cyclophosphamide IV and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5 and rituximab IV on days 1 and 8, and high-dose methotrexate IV with leucovorin calcium IV rescue on day 8. Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 3 and continuing until blood counts recover. Treatment repeats approximately every 14 days for 2 courses.

- CNS therapy: Patients receive cytarabine intrathecally (IT) with or without hydrocortisone IT on days 1, 4, and 11 of each induction therapy course. Patients with evidence of CNS involvement by lymphoma continue to receive cytarabine IT twice weekly during any induction therapy treatment delay. Patients who demonstrate CSF clearance receive cytarabine IT once weekly for 4 doses and then once every other week for 4 doses during consolidation therapy. Patients with disease progression during induction therapy or persistent CNS involvement by lymphoma are removed from the study. All other patients proceed to consolidation therapy.

- Consolidation therapy: Patients receive rituximab IV on day -4 and high-dose cyclophosphamide IV on days -3, -2, -1, and 0. Patients receive G-CSF SC once daily beginning on day 6 and continuing until blood counts recover OR pegfilgrastim SC once on day 6. Patients then receive rituximab IV once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 3 years.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 3 years.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date August 2013
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender All
Age group 30 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of 1 of the following:

- Classic, sporadic Burkitt's lymphoma

- Burkitt's leukemia (FAB L3 acute lymphoblastic leukemia)

- Atypical Burkitt/Burkitt's-like lymphoma or leukemia, defined by the following criteria:

- Characteristic morphologic features

- High proliferative index AND Ki-67 = 85%

- Any stage allowed

- Newly diagnosed or untreated disease

- Steroids allowed

PATIENT CHARACTERISTICS:

Age

- 30 and over

Performance status

- Not specified

Life expectancy

- Not specified

Renal

- No known irreversible renal dysfunction that would preclude treatment with high-dose cyclophosphamide

Cardiovascular

- No known significant cardiac dysfunction that would preclude treatment with high-dose cyclophosphamide

Other

- Not pregnant or nursing

- No known HIV positivity

- No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- No prior chemotherapy for lymphoma

- A maximum of 2 prior doses of intrathecal chemotherapy are allowed

Endocrine therapy

- Not specified

Radiotherapy

- No prior radiation therapy for lymphoma

Surgery

- Prior complete or incomplete surgical resection of lymphoma allowed

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Filgrastim
5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
Rituximab
375 mg/m^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
Drug:
Cyclophosphamide
1500 mg/m^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
Cytarabine
100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Methotrexate
3 g/m^2 on Day 8 of each cycle of R-CVP.
Prednisone
100 mg on Days 1-5 of each cycle of R-CVP.
Hydrocortisone
50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Vincristine
1.4 mg/m^2 on Day 1 of each cycle of R-CVP.
Leucovorin
25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.

Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Drexel University College of Medicine - Center City Hahnemann Campus Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kasamon YL, Brodsky RA, Borowitz MJ, Ambinder RF, Crilley PA, Cho SY, Tsai HL, Smith BD, Gladstone DE, Carraway HE, Huff CA, Matsui WH, Bolaños-Meade J, Jones RJ, Swinnen LJ. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypica — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate Number of participants who have a complete or partial remission (2007 International Working Group criteria). Up to 3 months
Primary Overall Survival Percentage of participants alive at 1 year and at 3 years. 1 year and 3 years
Primary Event-free Survival Percentage of participants alive without relapse at 1 year and 3 years. 1 year and 3 years
Primary Percentage of Participants Experiencing Grade 3-5 Toxicity Percentage of participants experiencing at least one grade 3-5 adverse event (by CTCAE 3.0 criteria). Up to 2 years
Secondary Relapse Pattern Percentage of participants experiencing central nervous system (CNS) and systemic relapse. Up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1